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Abstract
Purpose—We evaluated the role of a poly(ethylene glycol) (PEG) surface coating to increase 
residence times and alter the cellular fate of nano- and microparticles delivered to the lung.
Methods—Three sizes of PRINT hydrogel particles (80×320 nm, 1.5 and 6 um donuts) with and 
without a surface PEG coating were instilled in the airways of C57/b6 mice. At time points of 1, 7, 
and 28 days, BALF and whole lungs were evaluated for the inflammatory cytokine Il-6 and 
chemokine MIP-2, histopathology, cellular populations of macrophages, dendritic cells (DCs), and 
granulocytes, and particulate uptake within these cells through flow cytometry, ELISAs, and 
fluorescent imaging.
Results—Particles of all sizes and surface chemistries were readily observed in the lung with 
minimal inflammatory response at all time points. Surface modification with PEGylation was 
found to significantly increase lung residence times and homogeneous lung distribution, delaying 
macrophage clearance of all sizes, with the largest increase in residence time observed for 80×320 
nm particles. Additionally, it was observed that DCs were recruited to the airway following 
administration of unPEGylated particles and preferentially associated with these particles.
Conclusions—Pulmonary drug delivery vehicles designed with a PEG surface coating can be 
used to delay particle uptake and promote cell-specific targeting of therapeutics.
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Drug delivery via the pulmonary route offers an alternative course of administration with 
tremendous therapeutic benefits (1). Respiratory drug delivery can target local lung diseases, 
such as asthma, COPD, lung cancer, and can also be used to delivery therapeutics 
systemically, including delivery of insulin for diabetes management, or antigens for 
vaccination (2–5). This drug delivery can be achieved through a variety of methods, ranging 
from traditional nebulizers and inhaler devices to more recent developments in dry powder 
(DPI) therapeutics, offering benefits of patient compliance and ease of administration (6, 7).
There remains a significant unmet need in the delivery of respiratory drugs to target or de-
target cells in the lung depending on the desired site of action of the therapeutic. Alveolar 
macrophages (AM or MΦ) often present a significant barrier to efficient pulmonary drug 
delivery applications because of i) their sequestration and undesirable clearance of certain 
deposited drug particles in the lung whose site of action involves non-macrophage targets, 
like aerosolized therapeutics targeted to the alveoli and epithelial cells (8, 9) or ii) by their 
protection and harboring of disease targets, such as infectious bacteria like tuberculosis, 
which makes it difficult to treat effectively (10). Because particles with geometric diameters 
of 2–3 microns have been shown to be preferentially taken up by AMs (11), large, porous 
particles (LPPs) (12) and swellable microparticles (13) were developed to deposit in the 
alveolar airspace and successfully avoid macrophage uptake due to their large (> 5 μm) 
geometric size. Alternatively, it has been suggested that nanoparticles can avoid the rigorous 
AM clearance faced by microparticles, as nanoparticles are not as rapidly internalized by 
AMs (6). Any such therapeutic carriers which could avoid macrophage uptake offer the 
potential to provide sustained controlled release to the airspace and possibly into systemic 
circulation. While this detargeting of AMs holds clear therapeutic potential, specific 
targeting of these and other lung cells may hold alternative therapeutic advantages. For 
example, dendritic cell (DC) uptake of particles containing an antigen may be advantageous 
for vaccine applications or immunomodulation therapies (14–19). Physicochemical particle 
properties targeting macrophages have also been explored for enhancing host defense and 
regulating immune responses, and may be required for successful treatment of tuberculosis 
(10, 20).
The addition of a poly(ethylene glycol) (PEG) surface coating to nanoparticles has been 
studied extensively for intravenous (IV) administration of drug carriers, as the increase in 
surface hydrophilicity can prevent protein opsonization, which in turn limits cellular uptake 
and extends circulation times (21–24). Given the overwhelming evidence of PEGylation in 
avoiding macrophage uptake in IV applications, PEGylation has also been investigated in 
the context of pulmonary drug delivery (25). PEGylation has been successfully used to 
extend the lung half-life of antibodies, small molecule drugs, and other proteins in the lung 
(25–28). Various particles containing PEG in their formulation have been evaluated for 
pulmonary delivery as novel carriers, such as liposomes, polymeric micelles, and 
dendrimers (25), while others have been further optimized for therapeutic effects, including 
gene delivery, vaccines, and lung cancer (25, 29–33). PEGylation has been studied on LPPs 
and swellable polymeric particles made of PEG, with emphasis placed on the final 
geometric size accounting for the increase in macrophage avoidance and sustained release 
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(13, 34). Finally, PEG coatings have also been studied in the lung in the context of 
mucocilliary transport, as a high density PEG coating can promote mucus penetration of 
nano- and micro-particles in the lung (35, 36). Alternative coatings have been explored in 
the lung, as a particle coating of phospholipid 1,2-dipalmitoylphosphatidylcholine (DPPC) 
was shown to reduce uptake in alveolar macrophages (37). Despite this extensive history of 
PEG in the lung, there has been surprisingly limited work done to explore the in vivo cellular 
fate and inflammatory response to micro- and nano-particles coated with PEG. Indeed, to 
our knowledge, there has not been a study to date which directly evaluates the role of a PEG 
surface coating on lung particle residence times.
To determine if PEGylation is a feasible approach for extending the residence time of a 
particle in the lung, we utilized the Particle Replication in Non-wetting Templates (PRINT) 
method, which allows for the precise control over many particle characteristics such as size, 
shape, composition, porosity, modulus, and surface functionality (38). PRINT particles have 
been previously demonstrated for pulmonary applications (5, 39, 40) and PRINT 
nanoparticles have also been successfully functionalized with a high density PEG coating 
(21). In this study, non-spherical polymeric hydrogel particles ranging from 80 nm to 6 μm 
in diameter were fabricated using PRINT and functionalized with a PEG coating. These 
particles were then instilled into the lungs of mice and particle uptake and residence time in 
the lung was determined by flow cytometry and confocal microscopy, with additional 




All studies were conducted in accordance with National Institutes of Health guidelines for 
the care and use of laboratory animals and approved by the Institutional Animal Care and 
Use Committee (IACUC) at UNC. All animals were maintained in pathogen-free facilities at 
UNC and were between 8 and 15 weeks of age. C57BL/6 were obtained from Jackson 
Laboratories.
Materials
Solvents and buffers of reagent grade and cell media were obtained by Fisher Scientific. 
PRINT 80 × 320nm, 1.5μm and 6μm donut molds were provided by Liquidia Technologies. 
Pre-particle reagents of 2-aminoethylmethacrylate (AEM), poly(ethylene glycol)700 
diacrylate (PEG700DA) and diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide (TPO) were 
obtained from Sigma; tetra(ethylene glycol) monoacrylate (HP4A) was synthesized in house 
via previously described methods (41). Particle dye maleimide-Dylight 650 was obtained 
from Fisher. Lipopolysaccharide (LPS) was obtained from Sigma Aldrich. Methoxy-PEG5k-
SCM was purchased from Creative PEGworks.
Fabrication of PEGylated Hydrogel PRINT Particles
Particles were composed of 10% PEG700DA (cross-linker) (Sigma), 67% hydroxyl-
tetraethylene glycol monoacrylate (HP4A, monomer), 20% 2-aminoethyl methacrylate 
Shen et al. Page 3













hydrochloride (AEM), 2% fluorescent dye (Dylight 650 Maleimide, Thermo Fisher), and 
1% 2,4,6-Trimethylbenzoyl-diphenyl-phosphineoxide (TPO, photoinitiator) (Sigma) by 
weight. This pre-particle solution was filled into a Fluorocur mold of the intended geometric 
shape and cross-linked in a UV curing chamber (λ=365 nm). Particles were then transferred 
from the filled mold onto a polyvinyl alcohol (PVOH) harvest layer. Water was used to 
dissolve away the harvesting layer and free particles were collected. PEG5k-succinimidyl 
carboxymethyl ester (PEG5k-SCM) was reacted with the amine functional handles resulting 
in a layer of PEG on the particle surface (21). Both PEGylated and unPEGylated particles 
were then succinylated to quench any remaining free amine groups.
Particle Characterization
Geometric particle dimensions were measured by scanning electron microscopy (SEM) 
analysis; samples were sputter-coated with 1–5 nm of Au/Pd (Cressington Scientific 
Instruments) and imaged by using Hitachi model S-4700. Particle zeta potential was 
measured using a Zetasizer Nano ZS (Malvern Instruments, Ltd.).
Fluorescent Microscopy of In vitro Macrophage Uptake
MH-S, a mouse alveolar macrophage cell line, (ATCC) was used for particle uptake 
experiments. Cells were plated at 4 × 104 cells/well in 8-well chamber slides (LabTek) 48 
hours before particle addition. Cells were dosed with 25 μg particles in media consisting of 
high glucose Dulbecco’s Modified Eagle Medium (DMEM) (Gibco) and 10% fetal bovine 
serum (FBS). Particles were incubated on the cells for 4 hours at 37°C with 5% CO2. After 
incubation, cells were washed with Dulbecco’s Phosphate Buffer Saline (PBS) solution and 
fixed with 4% paraformaldehyde (PFA) solution. Staining of actin (Alexa Fluor 555, 
Invitrogen) and DAPI (Vectashield, Vector Labs) of fixed cells was then performed. 
Fluorescent imaging of stained cells was performed on a Zeiss 710 laser scanning confocal 
microscope (Zeiss).
In vivo Lung Instillation
To assess PRINT particle uptake in the lungs of mice, 8–10 week old female C57Bl/6 mice 
(Jackson Laboratories) were anesthetized with isofluorane and 50 μL of a particle solution 
was orotracheally administered. The anesthetized animal was suspended via the incisors in a 
near vertical position. The tongue was retracted to prevent swallowing and the particle 
suspension was administrated to the mouth. To complete the dose and ensure uniform 
instillation, the mouse was then monitored for five to ten breaths in this vertical position, 
with the nose gently occluded to ensure aspiration. Particles were dosed at 50 μg per mouse 
in PBS solution. Administration of 50 μL PBS or 20 μg/50 μL lipopolysaccharide (LPS) 
served as negative and positive controls, respectively. At timepoints of one, seven, and 
twenty-eight days post-particle dose, mice were euthanized and broncheoalveolar lavage 
fluid (BALF) was collected and the whole lung was excised.
Tissue and Cell Preparation
BAL was performed by inserting a cannula in an incision in the trachea and flushing the 
lungs with 1 mL HBSS. For collection of BALF cells, three sequential 1 mL washes were 
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performed to ensure collection of all BALF cells; for protein analysis of the BALF, animals 
were lavaged with a single 1 mL wash to ensure a detectable concentration. BALF cells 
were obtained by centrifugation, separating BALF cells from supernatant. For single cell 
whole lung suspensions, lungs were resected, physically agitated and digested in 5 mg/mL 
Collagenase D, 20 units/mL DNase in HBSS with 2% FBS for 1 hr at 37°C. These cells 
were then passed through a 70 μm sieve. For histology sectioning, lungs were inflated 
through the cannulae with a mixture of 1:1 PBS:OCT using a gravity inflation; inflated 
lungs were embedded in OCT (Tissue-Tek) and flash frozen using an isopentane, dry ice 
slurry.
Flow Cytometry Analysis
Cells collected from BALF and single cell suspensions collected from homogenized whole 
lung were stained with a panel of fluorescent antibodies for flow cytometric analysis of 
particle uptake and cell populations. The following antibodies were used for staining 
(BioLegend): CD45-PacBlue, CD11c-PE, MHCII-PE-Cy7, and Ly6-G-AF700. Cells were 
fixed with 4% PFA in PBS after staining and kept at 4°C until analysis. Flow cytometry data 
was collected on the LSRII flow cytometer (BD Biosciences) and analyzed using FlowJo 
software (Tree Star).
To correct for slight differences in fluorescence between particle types, relative particle 
fluorescence was independently determined by using a SpectraMax M5 plate-reader. 
Particles containing DyLight650 were incubated at 50 μg/mL in PBS and fluorescent 
intensity of each particle size was measured at 672 nm following excitation at 652 nm. 
Fluorescence values from all particle sizes were then normalized to that of the 80×320 
particles and this ratio was used to adjust median fluorescence intensity (MFI) flow 
cytometry results.
Cytokine Analysis
Enzyme-linked immuno assay (ELISA) kits for interleukin 6 (IL-6, BD Biosciences) and 
macrophage inflammatory protein 2 (MIP-2, R & D Systems) were used to measure protein 
release in BALF supernatant and performed following manufacturer’s instructions.
Fluorescent Lung Tissue Staining
Frozen lung was sliced into 7 μm thick sections, fixed with acetone, and fluorescently 
stained for phalloidin (Alexa Fluor 555 Phalloidin, Molecular Probes), CD11c (AF888 anti-
mouse CD11c, BioLegend), and cell nuclei (DAPI, Thermo Scientific). Images were 
obtained on the Zeiss 710 confocal microscope.
Results
Fabrication and Characterization of PEGylated Hydrogel PRINT Particles
Three different particle shapes, 80×320 nm, 1.5 μm donuts, and 6 μm donuts composed of 
PEG700-DA and with amine-functional handles were fabricated using the PRINT method. 
SEM images show the monodispersity of the fabricated hydrogel particles (Figure 1). 
Methoxy-PEG5k-SCM was then conjugated to these particles (designated 80×320P, 1.5P, 
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6P) to provide a stealthing PEG layer on the surface. PEGylated and unPEGylated particles 
were indistinguishable by SEM. Any remaining free amine groups were quenched with 
succinic anhydride. Particles that were not PEGylated, (designated 80×320U, 1.5U, 6U), 
were also quenched with succinic acid so that all particle groups would have a comparable 
negative surface charge. The particles were then characterized by surface area, volume, and 
surface charge (Table 1).
PEGylation of particles significantly reduces uptake by macrophages in vitro
To confirm the surface modification of the particles with a PEG layer, particles with and 
without PEG surface modification were incubated in vitro with MH-S mouse alveolar 
macrophages at a dose of 25 μg / 40k cells. Cells were fixed and stained for fluorescent 
confocal microscopy 4 hours after particle dose. As seen in the confocal images (Figure 2), 
PEGylation significantly reduced particle uptake in macrophages for all particle sizes tested. 
As expected, the macrophages most readily internalized the unPEGylated 1.5 μm donuts 
compared to the other two particle sizes, as particles with geometric diameters of 1–5 
microns have been shown to be preferentially taken up by alveolar macrophages (11, 42).
Particle effects on cell populations and cytokine/chemokine response in the lung
Relative cell populations of macrophages (MΦ), dendritic cells (DCs), and granulocytes in 
the whole lung and bronchoalveolar lavage fluid (BALF) were analyzed by flow cytometry 
to determine the effect of particle administration on cell recruitment in the lung (Figure 3, 
representative cell gating in S. Figure 1A). Macrophages (CD45+CD11c+MHCIIlo) 
constituted the major cell type in the BALF, ranging between 85–99% of the total (Figure 
3A). DC (CD45+CD11c+MHCIIhi) percentages of total cells ranged from 1–5% (Figure 3B). 
Granulocyte (CD45+CD11c−Ly6G+) populations were negligible (Figure 3C) in the saline 
and particle-treated mice. The macrophage population was observed to change based on the 
size and surface modification of the particle dosed. One day after particle instillation, it was 
observed that in the 80×320 nm and 1.5 μm donut treated mice, the unPEGylated particles 
had a mean macrophage population that was 5% and 10% lower, respectively, than their 
PEGylated counterparts while there was no statistical difference between the 6 μm donuts of 
different surface modifications. This trend continues out to day seven for the 80×320 nm 
sized particles. The LPS-treated mice had a significant influx of granulocytes in the BALF at 
24 hours post-dose, such that the relative number of macrophages was decreased by 2-fold.
Interestingly, although the percentage of DCs in the BALF was low; there was a surface 
modification effect observed on the BALF DC population at 24 hours post-dose that 
compliments the macrophage population trends. More specifically, the percentage of DCs 
was 2.5 and 3.8 fold lower in the mice treated with the PEGylated particles verses the 
unPEGylated particles of the 80×320 nm and 1.5 μm donut shapes, respectively. This 
difference only occurs at the day one time-point, as no other significant differences in the 
DC cell populations between particle-treated mice occurs in the BALF collected on days 
seven and twenty-eight. The 80×320P and 1.5P DC populations were similar to that of saline 
treated mice (~1%), however, there was a significant increase in BALF DC populations of 
the other particle-treated mice compared to the saline control groups. The 80×320U, 1.5U, 
6U, and 6P particles had about a 4-fold increase in the DC population. Combined with the 
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macrophage population changes, this suggests an influx of DCs to the lung following 
particle administration of small, unPEGylated particles and both functionalities of 6 μm 
particles, which further suggests that both surface modification and particle size may play a 
role in the appearance of DCs in the BALF.
In the whole lung, macrophages, dendritic cells, and granulocytes typically make up less 
than 20% of the cell population as endothelial, epithelial, and interstitial cells comprise a 
greater majority of lung cells (Figure 3D–F, representative gating in S. Figure 1A). In these 
experiments, the macrophage, DC, and granulocyte populations ranged from 5–20%, 5–
15%, and 1–6% of the total whole lung cell population remaining after a BAL, respectively. 
Interestingly, the surface modification effect seen on the DCs in the BALF is not replicated 
in the whole lung. After 24 hours, the particle-dosed mice had 50% fewer macrophages in 
the lung than the saline-dosed mice which may indicate macrophage recruitment from the 
interstitium to the airspace to assist in particle clearance. Similar to the BALF, LPS-treated 
mice had a significant influx of granulocytes in the lung and the relative number of 
macrophages in the lung tissue was decreased by 8-fold. Slight increases in the granulocyte 
population in both BALF and lung was observed with the 6 μm particles at one day post-
dose, but reverted back to saline levels at later time points. No other statistical difference 
between cell populations of the particle-treated mice was observed at one, seven, or twenty-
eight days in the whole lung.
Lung architecture and cell infiltration was also analyzed by lung histology (Figure 4). Cell 
infiltration was noticeable only in the unPEGylated 6 μm donuts one day post dose. All 
other particles doses at one, seven, and twenty-eight days showed no change in lung 
architecture or infiltration of granulocytes to the lung, corresponding to flow cytometry 
results.
Previous studies have shown that PRINT PEG hydrogel particles do not induce an 
inflammatory response of TNF-α, IL-1β, and IL-6 production in the lung out to 14 days 
(40). In this work, IL-6 and MIP-2, a mouse macrophage inflammatory protein plays a key 
role in neutrophil recruitment, was analyzed in BALF collected at one, seven, and twenty-
eight days after particle administration. By ELISA, detectable levels of IL-6 and MIP-2 were 
only seen one day post particle instillation (Figure 5).
Surface modification of particles affects particle retention time and cellular uptake in the 
lung
To determine particle size and surface modification effects on particle retention time and 
cellular uptake in the lung, flow cytometry was run on collected BALF and whole lung cells. 
Using the same flow cytometry gating as shown in S. Figure 1B, macrophage, DC and 
granulocyte populations were again identified and evaluated for particles containing Dylight 
650 dye, thus allowing uptake in specific cell populations to be determined by flow 
cytometry analysis. The percentage of particle positive cells within a population was 
determined for BALF macrophages (Figure 6A), lung macrophages (Figure 6D), and lung 
DCs (Figure 6G). From the particle positive gate, the median fluorescence intensity (MFI), 
or the average amount of fluorescence per cell, was also determined. This value is a measure 
of the volume of particles taken up by each particle positive cell type (Figure 6B, E, and H) 
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and has been normalized based on the relative fluorescence intensity of the particles. In 
addition, the total fluorescence was calculated by multiplying the number of positive particle 
cells by the MFI in order to give an overall view of the total volume of particles internalized 
(Figures 6C, F, and I).
Unlike what was seen in vitro, macrophages in the BALF were non-discriminating of 
surface modification for the smaller 1.5 μm donuts and 80×320 nm particles at one day post 
instillation with over 80% of macrophages having taken up particles. Yet, at day 28, the 
PEGylated 80×320 nm particles were present in 60% of BALF macrophages versus only 
20% for their unPEGylated counterparts, indicating a time-dependent surface modification 
response to particle uptake and/or clearance. With the larger 6 μm donuts, the macrophages 
had preferential uptake of the unPEGylated particles at one and seven days post-dose with 
no uptake seen at day 28. Because particles were dosed by mass and not by number, the 
reduced percentage of particle positive cells for the 6 μm donut instilled mice may be due to 
a reduced surface area coverage of the particles in the lung. In addition, the significantly 
larger volume of the 6 μm donut may also play a role in reduced uptake by macrophages.
The MFI data normalizes the volume of particles taken up by each particle positive cell. In 
BALF macrophages (Figure 6B), the MFI of the cells that were associated with the 6 μm 
donuts was 2–3 times greater than that of the other shapes at one day post-dose, indicating a 
larger mass of particles per cell. After one day, there was a 1.6-fold reduction in MFI of the 
80×320P particle positive macrophages compared to that of the 80×320U and a 3-fold 
reduction in MFI of the 1.5 P particles compared to the 1.5 U particles after 1 day. This 
indicates that a greater number of unPEGylated particles were initially taken up by 
macrophages, thus, surface modification may affect the propensity and degree of particle 
uptake in vivo. At day twenty-eight, the MFI levels of all particles were extremely low, yet, 
as mentioned previously, over 60% of macrophages in the BALF were particle positive for 
PEGylated 80×320 nm particles. We hypothesize that the PEG layer provides a delay in 
macrophage uptake, continuing through day 28. This may indicate that macrophage 
clearance and/or turnover rates can be affected by surface modification as well, with the 
addition of a PEG layer being able to prolong particle residence time in the lung.
The total fluorescence data for BALF macrophages (Figure 6C), shows a clear pattern in the 
effects of surface modification on particle uptake. At 24 hours post-dose, there is a 1.5, 3.4, 
and 3.7 fold difference between surface modified and unmodified 80×320 nm, 1.5 μm donut, 
and 6 μm donut particles, respectively, indicating that PEGylation of particles can 
significantly reduce uptake by macrophages in the lung of both nanoparticles and 
microparticles, with perhaps a stronger influence on microparticles. Interestingly, at day 
seven, the total fluorescence of the 80×320P particles remains at similar levels to those at 
day one which suggests slower clearance of macrophages with these particles and/or 
continued uptake of free particles residing in the alveolar space. This hypothesis is 
supported by the fact that the 80×320U particles have a 3.2 fold reduction in total 
fluorescence between days one and seven, implying clearance of particle loaded 
macrophages from the BALF and/or fewer free particles for further uptake by alveolar 
macrophages.
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In macrophages from the lung tissue (Figure 6D), the trends in percent particle positive cells 
are identical to that of the BALF macrophages. Surface modification again does not play a 
role in the number of particle positive cells one day after instillation with 80×320 nm and 
1.5 μm donut particles. However, unlike in the BALF, the 1.5 μm donut particles had 20% 
less particle positive cells than the 80×320 nm particles. This indicates a higher preference 
of the 80×320 nm particles to lung-residing macrophages compared to the other two particle 
sizes. Interestingly, the percentage of 80×320 nm positive cells increases from day one to 
day seven, suggesting that there may be free particles residing in the alveolar space which 
are not immediately internalized by cells in the lung. The unPEGylated 6 μm donuts have 
over a 5-fold increase in particle positive cells versus the PEGylated particles at both one 
and seven days post-instillation. In both the BALF and the lung, surface modification on 
larger micron-sized (6 μm) particles has a greater effect on uptake at early time points than 
modifications on smaller (80×320 nm and 1.5 μm) particles.
The MFI data for the lung macrophage population (Figure 6E) is quite different from that of 
the BALF. While the fluorescence intensity of the 80×320 nm particles and 1.5 μm donuts at 
day one are similar in intensity to that of the BALF, the 6P and 6U particles in the lung 
tissue had a 25% and 98% reduction in MFI, respectively. This indicates that macrophages 
in the BALF are associated with a greater number of 6 μm particles compared to 
macrophages in the lung tissue, and that the unPEGylated particles are more quickly cleared 
from the lung cells. In furthering the evidence of 80×320P particles having the ability to be 
retained in the lung both free and in macrophages, the MFI value of these particles increases 
2-fold from day one to day seven. One would expect that if only the macrophage clearance 
rate was reduced, that the MFI levels would have a slower rate of decay, but would not 
increase over time. Because the percent particle positive cells and the MFI increase over 
time, this indicates that additional particles may be continually taken up by macrophages in 
the lung, and are retained within the lung tissue, rather than being cleared to the BALF 
macrophages. At twenty-eight days post-instillation, all particle MFIs are significantly 
reduced and no difference is seen between particle types.
While the total fluorescence data from macrophages in the BALF indicated a preference for 
unPEGylated particles at one day post-dose, the total fluorescence data from macrophages in 
the lung (Figure 6F) shows no effect of surface modification on the total volume of particles 
internalized. For the longer seven and twenty-eight day time points, the trends hold from the 
MFI data, indicating an increase in particle uptake of 80×320 P particles from day one to 
day seven and then a clearance of particle-loaded macrophages by day twenty-eight.
Unlike the macrophages in both the BALF and the lung, DCs in the lung showed a 
preference for unPEGylated particles one day post-dose (Figure 6G). Particle uptake of 
unPEGylated particles increased by 2.0, 4.2, and 1.6-fold in 80×320 nm, 1.5 μm, and 6 μm 
particles, respectively compared to their PEGylated counterparts. At days seven and twenty-
eight, surface modification effects are no longer seen. Interestingly, although there was a 
higher percentage of particle positive cells with the 80×320 U particles, the MFI data 
indicates that DCs in the lung have a much higher preference for 1.5 μm donuts, and in 
particular, the unPEGylated 1.5 μm donuts (Figure 6H). One caveat for the MFI analysis is 
demonstrated with the 6 μm donut particles at days seven and twenty-eight. Because MFI 
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analyzes the median fluorescence intensity of only particle positive cells, and because of the 
extremely low percentage of particle positive DCs containing 6 μm donuts (all less than 
0.2%), the MFI may not be truly representative of the population and inferences of the data 
may not be relevant. The vertical axis of the total fluorescence graph of lung DCs (Figure 
6I) is an order of magnitude lower than that of the BALF and lung macrophages, but it 
follows the trend of the MFI data, indicating a strong preference for unPEGylated 1.5 μm 
particles at one day post-dose. At day seven, the total fluorescence equalizes among the 
80×320 nm and 1.5 μm particles which suggests that there may be a homeostatic effect in 
regulating the volume of particles within DCs in the lung.
These results indicate that there are significant differences in particle uptake and clearance 
among difference resident lung cell populations. In addition, surface modification, and in 
this case, PEGylation, of both nano- and micron-sized particles affects particle uptake and 
retention in the lung. PEGylated 80×320 nm particle uptake in BALF and lung macrophages 
is seen out to twenty-eight days, suggesting a slower clearance rate of these cells and/or 
continued uptake of free particles in the alveolar region.
Particle Distribution in the Lung Tissue
To observe the distribution of the particles within the lung tissue, sections of frozen lung 
tissue were stained for actin, cell nuclei, and CD11c followed by analysis via fluorescent 
microscopy (Figure 7). As expected, more 80×320 nm particles were observed in the lung 
tissue due to the number dosed as compared to the micron-sized particles. Interestingly, the 
PEGylated 80×320nm particles were shown to have a more homogeneous deposition 
throughout the lung tissue. Because of this higher distribution in the lung epithelium, the 
retention time of these particles may be extended, supporting the flow cytometry data which 
shows that PEGylated 80×320 nm particles can remain in the lung out to twenty-eight days. 
The unPEGylated 80×320 nm particles were shown to be less evenly distributed in the lung 
and were often seen in larger aggregates than the unPEGylated particles. More free 
PEGylated 1.5 μm particles were also observed compared to their unPEGylated 
counterparts. There were no differences in particle distribution in the lung with the 6 μm 
particles.
Discussion
The ease of access, large absorptive surface area, and reduced enzymatic activity of the lung 
make it an attractive target for both local and systemic drug delivery, yet drug carriers must 
circumvent the lung’s highly efficient particle clearance mechanisms in order to successfully 
deliver their payload. In addition, the drug delivery vehicles must be inert, preferably not 
contributing to an adverse inflammatory response. While there are a multitude of studies in 
environmental toxicology analyzing the retention and inflammatory effects of polystyrene, 
pollutant and industrial (diesel exhaust, dust, carbon fiber) particle burdens in the lung (43, 
44), there is a growing interest in studying the effect of lung drug carriers, especially of a 
controlled design (13, 32, 40). In this study, we observed the effects of size and surface 
modification on polymeric particles on particle retention and potential inflammatory 
consequences in the lung. The findings from these studies may help articulate important 
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particle parameters towards designing more efficient pulmonary drug delivery vehicles. 
Here, we utilized PRINT technology to fabricate monodisperse, cross-linked hydrogel 
particles of nanometer and micrometer sizes that were further modified by adding an 
additional PEG layer to the particle surface.
The orientation of the PEG layer on the particle surface is known to directly impact the 
particle’s interaction with various cells and proteins. In particular, a “brush” conformation, 
where the PEG chains are roughly perpendicular to the particle surface, is considered a 
requirement to hinder cellular internalization (21, 45). The method used to functionalize the 
particles studied here has been previously established in our lab to ensure a brush 
conformation on 80×320 nm hydrogel particles of the same chemistry (21). While PEG 
density was not explicitly evaluated for the other two sizes used in this study, we assume 
that all particle sizes also have a brush conformation. PEG conformation is dictated by the 
relationship of Flory radius and the pinning distance of PEG chains on the particle surface 
(46). The calculated Flory radius, as calculated in ref. (21), remains the same regardless of 
particle size, as the PEG molecular weight and solvent conditions remain unchanged. This 
leaves potential changes in the pinning distance between PEG chains. This pinning distance 
is based on the frequency of reactive groups and the particle surface area. As identical 
particle chemistry is used for all sizes, the frequency of the reactive groups on the particle 
surface is assumed to be equivalent, ensuring a PEG brush conformation.
Our results support the assumed brush PEG conformation on all particle sizes. The in vitro 
results in MH-S cells showed dramatic reduction in internalization over the 4 hr time point 
and all three PEGylated particles showed decreased cellular uptake and increased lung 
residence time in vivo compared to their unPEGylated counterparts. To our knowledge, this 
is one of the first reports of PEGylated micron-sized particles avoiding biological clearance 
mechanisms, as particles of this size range can only feasibly be delivered via inhalation. 
Indeed, all three sizes of particles in this study were identified to have aerodynamic 
diameters under 5 microns to facilitate aerosol delivery, regardless of their geometric size 
(39). Given this large spectrum of sizes, we were originally unsure if a 5k molecular weight 
PEG would be sufficient to provide the observed adequate stealthing properties to micron-
sized particles. There is evidence in the literature to suggest that PEG molecular weight and 
pinning density can be further optimized within the brush conformation to have enhanced 
reduction of cellular uptake (47). Future work exploring the role of PEG molecular weight 
and pinning density to enhance the observed PEGylation effects on micron-sized particles, 
especially in the lung, is needed and currently ongoing in our group.
In the studies presented here, we evaluated the three sizes of particles dosed at equivalent 
mass. We chose this dosing strategy to evaluate particle size as a formulation strategy for 
delivering an equivalent mass of a potential therapeutic agent. Thus, the flow cytometry 
results of percent positive cells would correspond to the number cells directly interacting 
with the therapeutic, the MFI would correspond to an approximation for the total dose per 
cell, and the total fluorescence would correspond to the total dose contained in the collected 
cellular compartment. Given the large difference in geometric size and thus volume between 
the particle set, considerable differences in particle number exists between the sizes. Dosing 
by equivalent particle number would increase the frequency of micron-sized particles in the 
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cellular compartment and may impact the observed inflammatory response. Thus, some of 
the results presented here are likely an artifact of the differences in particle number dosed. 
Previous work from our group has shown potential benefit of dosing by an equivalent mass 
of therapeutic but different particle number through varied drug loadings within particles to 
increase therapeutic efficacy (48). However, in this work, we assume that the same mass of 
therapeutic would be loaded into each particle size in order to directly compare the benefit 
of each size and surface chemistry.
We were especially interested in making these comparisons within key lung populations 
following pulmonary delivery by utilizing flow cytometry to determine the cellular fate of 
the particles. Flow cytometry is an especially attractive approach for evaluating particle 
formulations and is finding increased application in drug delivery applications, especially 
toward targeting specific cell types. The lung represents a challenging organ in phenotypic 
identification of the cells identified here, as many subtypes of these cells will express 
varying amounts of markers that are traditionally used to distinguish cells in other organs. 
For example, AMs express high levels of CD11c, traditionally considered a DC marker, and 
a subset of DCs (CD11b+ DCs) can express F4/80, traditionally considered a macrophage 
marker (19). The gating scheme chosen to broadly identify DCs and macrophages is shown 
in Supplemental Figure 1 and uses major histocompatibility complex (MHC) II expression 
to distinguish macrophages and DCs, which assumes a non-inflamed lung environment. This 
is supported by previous work in our group and the cytokine and histology results in Figures 
4 and 5. We are currently exploring more complex flow cytometry strategies to evaluate 
particle association in some of these critical macrophage and DC subtypes, which may have 
further application in vaccine and cancer therapeutics.
For therapeutic applications targeting sentinel dendritic cells, our flow cytometry findings 
show that lung DCs have a significant preference for unPEGylated 1.5 μm particles. Here, 
increasing the overall lung resident time by avoiding macrophage uptake did not enhance 
uptake in DCs. Although there are a higher percentage of particle positive DCs in the lung 
with the 80×320U particles, the total volume of internalized particles is over 3-fold greater 
for the 1.5U particles, indicating a clear preference for this size larger particle. From a more 
physiological view, we show that the DC population that migrates out to the airway surface 
can potentially be modulated by the surface modification of the particle; unPEGylated 
80×320 nm and 1.5 μm particles were shown to double the DC population in the BALF one 
day post-dose.
Interestingly, although the in vitro macrophage uptake studies showed that PEGylated 
particles of all three particle sizes tested had a significant decrease in number of cells with 
particle positive cells compared to their unPEGylated counterparts, only the 6 μm donut 
particles followed this trend in BALF and lung macrophages with a 2-fold and 5-fold 
decrease in particle positive cells, respectively. This indicates that PEGylated 6 μm donuts 
may be promising drug carriers as well for disease targets where de-targeting macrophage 
uptake is preferred. These particles have a large geometric size to avoid macrophage uptake, 
which is further enhanced with a PEG surface coating. Taking into account total 
fluorescence, or overall amount of particles internalized, there was indeed a difference due 
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to surface modification of all particle sizes in the BALF indicating the ability to reduce mass 
of particles taken up by immune cells in the lung via surface PEGylation.
Our results show that these particles can reside in the lung out to twenty-eight days without 
causing an inflammatory response. This supports previous work from our group, which 
found that these particles did not activate the inflammasome following pulmonary delivery 
(40). In this work, we also measured the BALF for MIP-2, a chemokine responsible for 
neutrophil recruitment. These cytokine and chemokine data correspond to the immune cell 
recruitment seen in the flow cytometry analysis of the cell populations in the BALF: both 
the 80×320U and the 6U dosed mice had slightly elevated granulocyte levels at day one 
compared to saline. Interestingly, histopathology on these samples shows no significant 
neutrophil recruitment to the lungs. Other protein analysis of the potential acute 
inflammatory response to these particles, including analysis of lung-specific molecules such 
as surfactant proteins A and D (SP-A and SP-D respectively) or total mucin content, may 
lend increase insight to the cellular recruitment process (49–51). Importantly, no long term 
inflammatory response was observed at the 28 day time point.
At this long time point, the 80×320 nm and 1.5 μm particles were still observed in BALF 
and lung cells, which may make them a prime candidate for sustained release of drug for 
diseases targeting macrophages in the lung, such as tuberculosis. Additionally, the 
PEGylated 80×320 nm actually show an increase in uptake from day one to day seven, 
indicating that there are likely free particles residing in the alveolar airspace and/or epithelial 
tissue. This is supported by fluorescent microscopy of the lung tissue which shows the 
particles significantly distributed throughout the epithelial cells of the lung. In contrast, the 
unPEGylated particles were more likely to be internalized by cells, explaining the punctate 
distribution in the lung that implies cellular internalization. The PEGylated particles were 
not as prone to uptake thus increasing retention and duration on the lung surface. This 
increased homogeneity in lung distribution may have also resulted from PEGylated particles 
ability to better interact with the mucus and surfactants within the airway. This may make 
these particles ideal for gene delivery to treat cystic fibrosis and local delivery of 
therapeutics to airway cells to treat chronic obstructive pulmonary disease (COPD).
Conclusions
In this work, the role of PEGylation to increase residence times and alter the cellular fate of 
nano- and microparticles delivered to lung was evaluated. Not only are these particles non-
inflammatory, but they were found to be retained in the lung for at least a month, with 
potential to serve as drug depots. Surface modification with PEGylation was found to 
significantly affect uptake kinetics by key cell populations in the lung, thus allowing for 
cell-specific targeted delivery of therapeutics. Particularly, PEGylation was found to 
increase lung residence times of all sizes of particles tested here, with the largest increase in 
residence time observed for smaller 80×320 nanometer particles. Additionally it was 
observed that DCs preferred smaller unPEGylated particles. By tuning the particle size and 
surface chemistry, design rules for targeted cellular pulmonary delivery are beginning to 
emerge. Applying the knowledge from these fundamental biological studies of particle 
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interactions in the lung can lead to the design of more efficient drug carriers for a variety of 
pulmonary delivery applications.
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SEM images of PRINT hydrogel particles. (A) 80×320 nm, (B) 1.5 μm donut, (C) 6 μm 
donut.
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Particles dosed to MH-S cells at 25 μg/40 k cells and imaged 4 hours post-dose. Particles 
(red), Nuclei (blue), Actin (green). Representative images from n=3 independent 
experiments.
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Relative populations of macrophages, dendritic cells (DC) and granulocytes in (A–C) BALF 
and (D–F) whole lung as determined by flow cytometry analysis (BALF representative 
gating in Supplemental Figure 1, lung in Supplemental Figure 2). Saline and LPS cell 
populations analyzed only at 1 and 7 days post-dose. Average values shown (n=4 animals) 
+/− standard deviation. Analysis by two-way ANOVA with Tukey multiple comparisons 
test; * p < 0.05, ** p < 0.001, *** p < 0.0001.
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H&E stained lung tissue 24 hours after particle dose. (Scale bar = 200 μm, 2x magnification) 
Representative images from n=4 animals.
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IL-6 cytokine and MIP-2 chemokine levels measured from BALF 24 hours post-instillation. 
Average values shown (n=4 animals) +/− standard deviation.
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Flow cytometry analysis of particle uptake, median fluorescence intensity (MFI) of particle 
positive cells, and total fluorescence. (A–C) BALF macrophage, (D–F) lung macrophage 
and (G–I) lung DCs at 1, 7 and 28 days post-instillation. Average values shown (n=4 
animals) +/− standard deviation. Two-way ANOVA with Tukey multiple comparisons test; 
* p < 0.05, ** p < 0.001, *** p < 0.0001).
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Particle distribution in the lung 1 day post-instillation. Particles (red), Actin (gray), Nuclei 
(blue), CD11c (green). Representative images from n=4 animals.
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Table 1
Particle characterization of surface area (SA), volume (Vol), and charge. Values from a representative batch of 
particles.
SA (μm2) Vol (μm3) Zeta Potential (mV)
Particle UnPEGylated PEGylated
80×320 nm 0.097 .0018 −34.7 −28.5
1.5 μm Donut 5.655 0.79 −25.3 −32.3
6 μm Donut 88.593 40.68 −5.6 −31.3
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